Loading…
Comorbidity in US patients with multiple sclerosis
To assess the trends in the prevalence of comorbidities in US patients with multiple sclerosis (MS), and the association of demographic characteristics with the presence of comorbidities. A retrospective analysis was conducted from a sample of 5 million patients from the IMS Health Real World Data A...
Saved in:
| Published in: | Patient related outcome measures 2018-01, Vol.9, p.97-102 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c549t-435587488c734d3d3582f0eb4a715bde6bd93b1931cd77441fb9cad8a2131b463 |
|---|---|
| cites | |
| container_end_page | 102 |
| container_issue | |
| container_start_page | 97 |
| container_title | Patient related outcome measures |
| container_volume | 9 |
| creator | Edwards, Natalie C Munsell, Michael Menzin, Joseph Phillips, Amy L |
| description | To assess the trends in the prevalence of comorbidities in US patients with multiple sclerosis (MS), and the association of demographic characteristics with the presence of comorbidities.
A retrospective analysis was conducted from a sample of 5 million patients from the IMS Health Real World Data Adjudicated Claims - US database.
Comorbidity in patients with MS was assessed by year (2006-2014), and logistic regression models evaluated the association of age, sex, and region with select comorbidities.
The most common comorbidities from 2006 to 2014 were hyperlipidemia and hypertension (25.9%-29.7% of patients within an individual year), followed by gastrointestinal disease (18.4%-21.2% of patients) and thyroid disease (12.9%-17.1% of patients). The proportion with a claim for hyperlipidemia increased from 2006 to 2009, was stable from 2009 to 2011, and then declined from 2011 to 2014. The proportion with a claim for hypertension generally increased from 2006 to 2013, then declined from 2013 to 2014. The proportion with a claim for gastrointestinal disease, thyroid disease, and anxiety generally increased from 2006 to 2014. Claims for comorbidities were statistically significantly more likely among older age groups ( |
| doi_str_mv | 10.2147/PROM.S148387 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_13d6758a16a749ac86ca15a1f59cb937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A582623333</galeid><doaj_id>oai_doaj_org_article_13d6758a16a749ac86ca15a1f59cb937</doaj_id><sourcerecordid>A582623333</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-435587488c734d3d3582f0eb4a715bde6bd93b1931cd77441fb9cad8a2131b463</originalsourceid><addsrcrecordid>eNptUl1rFDEUDaLYsvbNZxkQxAd3nZuPSfIilMWPQqViLfgWMklmN2Vmsk0ySv-9WXetu-LNQ8LNuSf3nhyEnkO9wED52y9frz4vroEKIvgjdArA5Rxz-P744HyCzlK6rUvQGnNGn6ITLKkEjskpwsswhNh66_N95cfq5rra6OzdmFP10-d1NUx99pveVcn0Lobk0zP0pNN9cmf7fYZuPrz_tvw0v7z6eLE8v5wbRmWeU8KY4FQIwwm1xBImcFe7lmoOrLWuaa0kLUgCxnJOKXStNNoKjYFASxsyQxc7Xhv0rdpEP-h4r4L26ncixJXSMfvSlgJiG86EhkZzKrURjdHANHRMmlYSXrje7bg2Uzs4a8p8UfdHpMc3o1-rVfihmABW1C0Er_cEMdxNLmU1-GRc3-vRhSkpXNeSNQ0vzc_Qy3-gt2GKY5FKYVyU54zU9V_USpcB_NiF8q7ZkqrzolSDyTZmaPEfVFnWDd6E0XW-5I8KXh0UrJ3u8zqFfso-jOkY-GYHNOVTU3TdgxhQq6231NZbau-tAn9xKOAD-I-TyC9s0sXL</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2229475300</pqid></control><display><type>article</type><title>Comorbidity in US patients with multiple sclerosis</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Taylor & Francis (Open access)</source><creator>Edwards, Natalie C ; Munsell, Michael ; Menzin, Joseph ; Phillips, Amy L</creator><creatorcontrib>Edwards, Natalie C ; Munsell, Michael ; Menzin, Joseph ; Phillips, Amy L</creatorcontrib><description>To assess the trends in the prevalence of comorbidities in US patients with multiple sclerosis (MS), and the association of demographic characteristics with the presence of comorbidities.
A retrospective analysis was conducted from a sample of 5 million patients from the IMS Health Real World Data Adjudicated Claims - US database.
Comorbidity in patients with MS was assessed by year (2006-2014), and logistic regression models evaluated the association of age, sex, and region with select comorbidities.
The most common comorbidities from 2006 to 2014 were hyperlipidemia and hypertension (25.9%-29.7% of patients within an individual year), followed by gastrointestinal disease (18.4%-21.2% of patients) and thyroid disease (12.9%-17.1% of patients). The proportion with a claim for hyperlipidemia increased from 2006 to 2009, was stable from 2009 to 2011, and then declined from 2011 to 2014. The proportion with a claim for hypertension generally increased from 2006 to 2013, then declined from 2013 to 2014. The proportion with a claim for gastrointestinal disease, thyroid disease, and anxiety generally increased from 2006 to 2014. Claims for comorbidities were statistically significantly more likely among older age groups (
<0.05), with the exception of anxiety and alcohol abuse, which were statistically significantly less likely among older age groups. Claims for gastrointestinal disease (OR=0.75), thyroid disease (OR=0.36), chronic lung disease (OR=0.76), arthritis (OR=0.71), anxiety (OR=0.63), and depression (OR=0.69) were statistically significantly less likely among males versus females (all
<0.05). Claims for hyperlipidemia (OR=1.39), hypertension (OR=1.25), diabetes (OR=1.31), and alcohol abuse (OR=2.41) were significantly more likely among males (
<0.05). Many comorbidity claims were statistically significantly more likely in the Northeast and South compared with the Midwest and West.
This study provides select comorbidity claims estimates in US patients with MS, and thus highlights the importance of comprehensive patient care approaches.</description><identifier>ISSN: 1179-271X</identifier><identifier>EISSN: 1179-271X</identifier><identifier>DOI: 10.2147/PROM.S148387</identifier><identifier>PMID: 29491723</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Alcohol abuse ; Alcoholism ; Analysis ; Arthritis ; comorbidities ; Comorbidity ; Depression (Mood disorder) ; disease-modifying drugs ; Gastrointestinal diseases ; Hyperlipidemia ; Hypertension ; Medical research ; Mortality ; Multiple sclerosis ; Original Research ; prevalence ; Respiratory tract diseases ; Suicides & suicide attempts ; Thyroid diseases</subject><ispartof>Patient related outcome measures, 2018-01, Vol.9, p.97-102</ispartof><rights>COPYRIGHT 2018 Dove Medical Press Limited</rights><rights>2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 Edwards et al. This work is published and licensed by Dove Medical Press Limited 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-435587488c734d3d3582f0eb4a715bde6bd93b1931cd77441fb9cad8a2131b463</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2229475300/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2229475300?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29491723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Edwards, Natalie C</creatorcontrib><creatorcontrib>Munsell, Michael</creatorcontrib><creatorcontrib>Menzin, Joseph</creatorcontrib><creatorcontrib>Phillips, Amy L</creatorcontrib><title>Comorbidity in US patients with multiple sclerosis</title><title>Patient related outcome measures</title><addtitle>Patient Relat Outcome Meas</addtitle><description>To assess the trends in the prevalence of comorbidities in US patients with multiple sclerosis (MS), and the association of demographic characteristics with the presence of comorbidities.
A retrospective analysis was conducted from a sample of 5 million patients from the IMS Health Real World Data Adjudicated Claims - US database.
Comorbidity in patients with MS was assessed by year (2006-2014), and logistic regression models evaluated the association of age, sex, and region with select comorbidities.
The most common comorbidities from 2006 to 2014 were hyperlipidemia and hypertension (25.9%-29.7% of patients within an individual year), followed by gastrointestinal disease (18.4%-21.2% of patients) and thyroid disease (12.9%-17.1% of patients). The proportion with a claim for hyperlipidemia increased from 2006 to 2009, was stable from 2009 to 2011, and then declined from 2011 to 2014. The proportion with a claim for hypertension generally increased from 2006 to 2013, then declined from 2013 to 2014. The proportion with a claim for gastrointestinal disease, thyroid disease, and anxiety generally increased from 2006 to 2014. Claims for comorbidities were statistically significantly more likely among older age groups (
<0.05), with the exception of anxiety and alcohol abuse, which were statistically significantly less likely among older age groups. Claims for gastrointestinal disease (OR=0.75), thyroid disease (OR=0.36), chronic lung disease (OR=0.76), arthritis (OR=0.71), anxiety (OR=0.63), and depression (OR=0.69) were statistically significantly less likely among males versus females (all
<0.05). Claims for hyperlipidemia (OR=1.39), hypertension (OR=1.25), diabetes (OR=1.31), and alcohol abuse (OR=2.41) were significantly more likely among males (
<0.05). Many comorbidity claims were statistically significantly more likely in the Northeast and South compared with the Midwest and West.
This study provides select comorbidity claims estimates in US patients with MS, and thus highlights the importance of comprehensive patient care approaches.</description><subject>Alcohol abuse</subject><subject>Alcoholism</subject><subject>Analysis</subject><subject>Arthritis</subject><subject>comorbidities</subject><subject>Comorbidity</subject><subject>Depression (Mood disorder)</subject><subject>disease-modifying drugs</subject><subject>Gastrointestinal diseases</subject><subject>Hyperlipidemia</subject><subject>Hypertension</subject><subject>Medical research</subject><subject>Mortality</subject><subject>Multiple sclerosis</subject><subject>Original Research</subject><subject>prevalence</subject><subject>Respiratory tract diseases</subject><subject>Suicides & suicide attempts</subject><subject>Thyroid diseases</subject><issn>1179-271X</issn><issn>1179-271X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUl1rFDEUDaLYsvbNZxkQxAd3nZuPSfIilMWPQqViLfgWMklmN2Vmsk0ySv-9WXetu-LNQ8LNuSf3nhyEnkO9wED52y9frz4vroEKIvgjdArA5Rxz-P744HyCzlK6rUvQGnNGn6ITLKkEjskpwsswhNh66_N95cfq5rra6OzdmFP10-d1NUx99pveVcn0Lobk0zP0pNN9cmf7fYZuPrz_tvw0v7z6eLE8v5wbRmWeU8KY4FQIwwm1xBImcFe7lmoOrLWuaa0kLUgCxnJOKXStNNoKjYFASxsyQxc7Xhv0rdpEP-h4r4L26ncixJXSMfvSlgJiG86EhkZzKrURjdHANHRMmlYSXrje7bg2Uzs4a8p8UfdHpMc3o1-rVfihmABW1C0Er_cEMdxNLmU1-GRc3-vRhSkpXNeSNQ0vzc_Qy3-gt2GKY5FKYVyU54zU9V_USpcB_NiF8q7ZkqrzolSDyTZmaPEfVFnWDd6E0XW-5I8KXh0UrJ3u8zqFfso-jOkY-GYHNOVTU3TdgxhQq6231NZbau-tAn9xKOAD-I-TyC9s0sXL</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Edwards, Natalie C</creator><creator>Munsell, Michael</creator><creator>Menzin, Joseph</creator><creator>Phillips, Amy L</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180101</creationdate><title>Comorbidity in US patients with multiple sclerosis</title><author>Edwards, Natalie C ; Munsell, Michael ; Menzin, Joseph ; Phillips, Amy L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-435587488c734d3d3582f0eb4a715bde6bd93b1931cd77441fb9cad8a2131b463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Alcohol abuse</topic><topic>Alcoholism</topic><topic>Analysis</topic><topic>Arthritis</topic><topic>comorbidities</topic><topic>Comorbidity</topic><topic>Depression (Mood disorder)</topic><topic>disease-modifying drugs</topic><topic>Gastrointestinal diseases</topic><topic>Hyperlipidemia</topic><topic>Hypertension</topic><topic>Medical research</topic><topic>Mortality</topic><topic>Multiple sclerosis</topic><topic>Original Research</topic><topic>prevalence</topic><topic>Respiratory tract diseases</topic><topic>Suicides & suicide attempts</topic><topic>Thyroid diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Edwards, Natalie C</creatorcontrib><creatorcontrib>Munsell, Michael</creatorcontrib><creatorcontrib>Menzin, Joseph</creatorcontrib><creatorcontrib>Phillips, Amy L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Patient related outcome measures</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Edwards, Natalie C</au><au>Munsell, Michael</au><au>Menzin, Joseph</au><au>Phillips, Amy L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comorbidity in US patients with multiple sclerosis</atitle><jtitle>Patient related outcome measures</jtitle><addtitle>Patient Relat Outcome Meas</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>9</volume><spage>97</spage><epage>102</epage><pages>97-102</pages><issn>1179-271X</issn><eissn>1179-271X</eissn><abstract>To assess the trends in the prevalence of comorbidities in US patients with multiple sclerosis (MS), and the association of demographic characteristics with the presence of comorbidities.
A retrospective analysis was conducted from a sample of 5 million patients from the IMS Health Real World Data Adjudicated Claims - US database.
Comorbidity in patients with MS was assessed by year (2006-2014), and logistic regression models evaluated the association of age, sex, and region with select comorbidities.
The most common comorbidities from 2006 to 2014 were hyperlipidemia and hypertension (25.9%-29.7% of patients within an individual year), followed by gastrointestinal disease (18.4%-21.2% of patients) and thyroid disease (12.9%-17.1% of patients). The proportion with a claim for hyperlipidemia increased from 2006 to 2009, was stable from 2009 to 2011, and then declined from 2011 to 2014. The proportion with a claim for hypertension generally increased from 2006 to 2013, then declined from 2013 to 2014. The proportion with a claim for gastrointestinal disease, thyroid disease, and anxiety generally increased from 2006 to 2014. Claims for comorbidities were statistically significantly more likely among older age groups (
<0.05), with the exception of anxiety and alcohol abuse, which were statistically significantly less likely among older age groups. Claims for gastrointestinal disease (OR=0.75), thyroid disease (OR=0.36), chronic lung disease (OR=0.76), arthritis (OR=0.71), anxiety (OR=0.63), and depression (OR=0.69) were statistically significantly less likely among males versus females (all
<0.05). Claims for hyperlipidemia (OR=1.39), hypertension (OR=1.25), diabetes (OR=1.31), and alcohol abuse (OR=2.41) were significantly more likely among males (
<0.05). Many comorbidity claims were statistically significantly more likely in the Northeast and South compared with the Midwest and West.
This study provides select comorbidity claims estimates in US patients with MS, and thus highlights the importance of comprehensive patient care approaches.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>29491723</pmid><doi>10.2147/PROM.S148387</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1179-271X |
| ispartof | Patient related outcome measures, 2018-01, Vol.9, p.97-102 |
| issn | 1179-271X 1179-271X |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_13d6758a16a749ac86ca15a1f59cb937 |
| source | Publicly Available Content Database; PubMed Central; Taylor & Francis (Open access) |
| subjects | Alcohol abuse Alcoholism Analysis Arthritis comorbidities Comorbidity Depression (Mood disorder) disease-modifying drugs Gastrointestinal diseases Hyperlipidemia Hypertension Medical research Mortality Multiple sclerosis Original Research prevalence Respiratory tract diseases Suicides & suicide attempts Thyroid diseases |
| title | Comorbidity in US patients with multiple sclerosis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A27%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comorbidity%20in%20US%20patients%20with%20multiple%20sclerosis&rft.jtitle=Patient%20related%20outcome%20measures&rft.au=Edwards,%20Natalie%20C&rft.date=2018-01-01&rft.volume=9&rft.spage=97&rft.epage=102&rft.pages=97-102&rft.issn=1179-271X&rft.eissn=1179-271X&rft_id=info:doi/10.2147/PROM.S148387&rft_dat=%3Cgale_doaj_%3EA582623333%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c549t-435587488c734d3d3582f0eb4a715bde6bd93b1931cd77441fb9cad8a2131b463%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2229475300&rft_id=info:pmid/29491723&rft_galeid=A582623333&rfr_iscdi=true |